Menu
Search
|

Menu

Close
X

Vascular Biogenics Ltd VBLT.OQ (NASDAQ Stock Exchange Global Market)

6.30 USD
-0.40 (-5.97%)
As of 2:29 AM IST
chart
Previous Close 6.70
Open 6.80
Volume 42,760
3m Avg Volume 57,138
Today’s High 6.80
Today’s Low 6.25
52 Week High 9.05
52 Week Low 3.95
Shares Outstanding (mil) 27.12
Market Capitalization (mil) 157.27
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
2.00 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
0
FY16
0
FY15
0
EPS (USD)
FY17
-0.609
FY16
-0.647
FY15
-0.736
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
32.90
Price to Sales (TTM)
vs sector
--
5.77
Price to Book (MRQ)
vs sector
4.45
5.41
Price to Cash Flow (TTM)
vs sector
--
23.42
Total Debt to Equity (MRQ)
vs sector
0.00
16.52
LT Debt to Equity (MRQ)
vs sector
0.00
12.22
Return on Investment (TTM)
vs sector
-42.25
14.43
Return on Equity (TTM)
vs sector
-42.33
16.13

EXECUTIVE LEADERSHIP

Bennett Shapiro
Chairman of the Board, Independent Director, Since 2007
Salary: --
Bonus: --
Dror Harats
Chief Executive Officer, Director, Since 2001
Salary: --
Bonus: --
Amos Ron
Chief Financial Officer & Company Secretary, Since 2016
Salary: --
Bonus: --
Eyal Breitbart
Vice President - Research & Operations, Since 2014
Salary: --
Bonus: --
Erez Feige
Vice President - Business Operations, Since 2014
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

6 Jonathan Netanyahu St.
OR YEHUDA     6037604

Phone: +9723.6346450

Vascular Biogenics Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of treatments for cancer. The Company's program is based on its Vascular Targeting System (VTS) platform technology, which utilizes genetically targeted therapy to destroy newly formed, or angiogenic, blood vessels. Its lead product candidate, VB-111(ofranergene obadenovec), is a gene-based biologic that it is developing for solid tumor indications, with a program for recurrent glioblastoma (rGBM), a form of brain cancer. It also is engaged in conducting a program focusing anti-inflammatory diseases, based on the use of its Lecinoxoid platform technology. Lecinoxoids are a class of small molecules it developed that are structurally and functionally similar to naturally occurring molecules known to modulate inflammation. The lead product candidate from this program, VB-201, is a Phase II-ready molecule.

SPONSORED STORIES